These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 21252750)

  • 21. Prenatal peptide treatment appears promising in Down syndrome mouse model.
    Levenson D
    Am J Med Genet A; 2013 Mar; 161A(3):ix. PubMed ID: 23436390
    [No Abstract]   [Full Text] [Related]  

  • 22. From vasoactive intestinal peptide (VIP) through activity-dependent neuroprotective protein (ADNP) to NAP: a view of neuroprotection and cell division.
    Gozes I; Divinsky I; Pilzer I; Fridkin M; Brenneman DE; Spier AD
    J Mol Neurosci; 2003; 20(3):315-22. PubMed ID: 14501014
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Altered expression of KIF17, a kinesin motor protein associated with NR2B trafficking, may mediate learning deficits in a Down syndrome mouse model.
    Roberson R; Toso L; Abebe D; Spong CY
    Am J Obstet Gynecol; 2008 Mar; 198(3):313.e1-4. PubMed ID: 18313453
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epigallocatechin-3-gallate (EGCG) consumption in the Ts65Dn model of Down syndrome fails to improve behavioral deficits and is detrimental to skeletal phenotypes.
    Stringer M; Abeysekera I; Thomas J; LaCombe J; Stancombe K; Stewart RJ; Dria KJ; Wallace JM; Goodlett CR; Roper RJ
    Physiol Behav; 2017 Aug; 177():230-241. PubMed ID: 28478033
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vasoactive intestinal peptide in the brain of a mouse model for Down syndrome.
    Hill JM; Ades AM; McCune SK; Sahir N; Moody EM; Abebe DT; Crnic LS; Brenneman DE
    Exp Neurol; 2003 Sep; 183(1):56-65. PubMed ID: 12957488
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protein dynamics associated with failed and rescued learning in the Ts65Dn mouse model of Down syndrome.
    Ahmed MM; Dhanasekaran AR; Block A; Tong S; Costa AC; Stasko M; Gardiner KJ
    PLoS One; 2015; 10(3):e0119491. PubMed ID: 25793384
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of chronic administration of SGS-111 during adulthood and during the pre- and post-natal periods on the cognitive deficits of Ts65Dn mice, a model of Down syndrome.
    Rueda N; Flórez J; Martínez-Cué C
    Behav Brain Res; 2008 Apr; 188(2):355-67. PubMed ID: 18178265
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term voluntary running modifies the levels of proteins of the excitatory/inhibitory system and reduces reactive astrogliosis in the brain of Ts65Dn mouse model for Down syndrome.
    Kida E; Walus M; Albertini G; Golabek AA
    Brain Res; 2021 Sep; 1766():147535. PubMed ID: 34043998
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neurotrophic effects of the peptide NAP: a novel neuroprotective drug candidate.
    Gozes I; Spivak-Pohis I
    Curr Alzheimer Res; 2006 Jul; 3(3):197-9. PubMed ID: 16842095
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brain deficits associated with fetal alcohol exposure may be protected, in part, by peptides derived from activity-dependent neurotrophic factor and activity-dependent neuroprotective protein.
    Sari Y; Gozes I
    Brain Res Rev; 2006 Aug; 52(1):107-18. PubMed ID: 16488478
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The GABA
    Block A; Ahmed MM; Rueda N; Hernandez MC; Martinez-Cué C; Gardiner KJ
    Neuroscience; 2018 Feb; 372():192-212. PubMed ID: 29292072
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acute injections of the NMDA receptor antagonist memantine rescue performance deficits of the Ts65Dn mouse model of Down syndrome on a fear conditioning test.
    Costa AC; Scott-McKean JJ; Stasko MR
    Neuropsychopharmacology; 2008 Jun; 33(7):1624-32. PubMed ID: 17700645
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NAP and ADNF-9 protect normal and Down's syndrome cortical neurons from oxidative damage and apoptosis.
    Busciglio J; Pelsman A; Helguera P; Ashur-Fabian O; Pinhasov A; Brenneman DE; Gozes I
    Curr Pharm Des; 2007; 13(11):1091-8. PubMed ID: 17430172
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased Sparsity of Hippocampal CA1 Neuronal Ensembles in a Mouse Model of Down Syndrome Assayed by Arc Expression.
    Smith-Hicks CL; Cai P; Savonenko AV; Reeves RH; Worley PF
    Front Neural Circuits; 2017; 11():6. PubMed ID: 28217086
    [TBL] [Abstract][Full Text] [Related]  

  • 35. α-Tocopherol suppresses lipid peroxidation and behavioral and cognitive impairments in the Ts65Dn mouse model of Down syndrome.
    Shichiri M; Yoshida Y; Ishida N; Hagihara Y; Iwahashi H; Tamai H; Niki E
    Free Radic Biol Med; 2011 Jun; 50(12):1801-11. PubMed ID: 21447382
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A flavonoid agonist of the TrkB receptor for BDNF improves hippocampal neurogenesis and hippocampus-dependent memory in the Ts65Dn mouse model of DS.
    Stagni F; Giacomini A; Guidi S; Emili M; Uguagliati B; Salvalai ME; Bortolotto V; Grilli M; Rimondini R; Bartesaghi R
    Exp Neurol; 2017 Dec; 298(Pt A):79-96. PubMed ID: 28882412
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peptide antagonists of ethanol inhibition of l1-mediated cell-cell adhesion.
    Wilkemeyer MF; Menkari CE; Spong CY; Charness ME
    J Pharmacol Exp Ther; 2002 Oct; 303(1):110-6. PubMed ID: 12235240
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NAP has no effect on spatial memory after short-term treatment in advanced stage Alzheimer's disease mouse model.
    Van Dijck A; Van Dam D; De Deyn PP
    Peptides; 2009 Dec; 30(12):2480-2. PubMed ID: 19664667
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Abnormal APP, cholinergic and cognitive function in Ts65Dn Down's model mice.
    Seo H; Isacson O
    Exp Neurol; 2005 Jun; 193(2):469-80. PubMed ID: 15869949
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Does the learning deficit observed under an incremental repeated acquisition schedule of reinforcement in Ts65Dn mice, a model for Down syndrome, change as they age?
    Sanders NC; Williams DK; Wenger GR
    Behav Brain Res; 2009 Oct; 203(1):137-42. PubMed ID: 19409933
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.